BROMPHENIRAMINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brompheniramine, and when can generic versions of Brompheniramine launch?
Brompheniramine is a drug marketed by Alpharma Us Pharms, Kv Pharm, Pharm Assoc, Usl Pharma, Watson Labs, Barr, Ivax Sub Teva Pharms, Newtron Pharms, Nexgen Pharma Inc, Par Pharm, Pioneer Pharms, Upsher Smith Labs, Vitarine, Acella, Alkem Labs Ltd, Bionpharma, Chartwell Molecular, Dr Reddys Labs Sa, Hibrow Hlthcare, Padagis Us, Rhodes Pharms, and Taro. and is included in twenty-six NDAs.
The generic ingredient in BROMPHENIRAMINE is brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride. There are twenty-one drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BROMPHENIRAMINE?
- What are the global sales for BROMPHENIRAMINE?
- What is Average Wholesale Price for BROMPHENIRAMINE?
Summary for BROMPHENIRAMINE
| US Patents: | 0 |
| Applicants: | 22 |
| NDAs: | 26 |
| DailyMed Link: | BROMPHENIRAMINE at DailyMed |

